Palatin Technologies (PTN) Current Leases (2011 - 2026)

Palatin Technologies' (PTN) quarterly Current Leases came in at $189205.0 in Q1 2026, down 13.89% on a QoQ basis from $219727.0 in Q4 2025.

Palatin Technologies (PTN) Current Leases (2011 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 13 years of Current Leases data on file, last reported at $189205.0 in Q1 2026.

Quarterly Current Leases changed N/A year-over-year to $189205.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189205.0 (changed N/A YoY) and the FY2025 annual result came in at $129812.0, up 182.11% from the prior year.
Current Leases fell to $189205.0 in Q1 2026, from $219727.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $371124.0 in Q2 2022 to a low of $18527.0 in Q3 2024.
A 5-year average of $162880.9 and a median of $118808.5 in 2023 frame the typical range for Current Leases.
Annual changes were most pronounced in 2024 — Current Leases slumped 87.0% — and 2025, when it jumped 614.88%.
Tracing PTN's Current Leases over 5 years: stood at $103622.0 in 2022, then decreased by 3.58% to $99912.0 in 2023, then jumped by 157.9% to $257673.0 in 2024, then retreated by 14.73% to $219727.0 in 2025, then dropped by 13.89% to $189205.0 in 2026.
The last three Current Leases figures came in at $189205.0 (Q1 2026), $219727.0 (Q4 2025), and $132446.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	138.76 Bn	130.91 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.15 Bn	78.15 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	64.45 Bn	59.27 Bn	1.37 Bn	-
4	Moderna	57.08 Bn	51.94 Bn	52.00 Mn	-
5	BeOne Medicines	42.08 Bn	36.99 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	30.90 Bn	27.59 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	27.76 Bn	9.37 Bn	668.28 Mn	-
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.00 Bn	26.17 Bn	-	-
10	Palatin Technologies	40.25 Mn	40.25 Mn	-	189,205.00

Download Data